Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 2/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203310 | 0.83 | PARP14 (0.40) | MAOBMAOAKMT2ACYP3A4PRKDC | |
| SCHEMBL311936 | 0.80 | PRKDC (0.45) | MAOBMAOACYP3A4PRKDCNMT1 | |
| SCHEMBL1232966 | 0.78 | MCHR1 (0.49) | MAOBCYP3A4NMT1KITGRM4 | |
| SCHEMBL205109 | 0.77 | PIK3CA (0.39) | KMT2A | |
| SCHEMBL1233388 | 0.74 | PRMT5 (0.39) | CYP3A4NMT1KITGRM4 | |
| SCHEMBL4239447 | 0.73 | NPC1 (0.49) | MAOBKMT2ACYP3A4KITGRM4 | |
| SCHEMBL1233682 | 0.71 | CYP8B1 (0.44) | NMT1KIT | |
| SCHEMBL1486437 | 0.69 | HRH3 (0.44) | MAOBMAOAKMT2ACYP3A4NMT1 | |
| SCHEMBL1232944 | 0.69 | CYP8B1 (0.47) | NMT1KIT | |
| SCHEMBL1486838 | 0.69 | BRD4 (0.46) | CYP3A4NMT1NMT2KITPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | MAOB 2963/4885MAOA 2282/4885KMT2A 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.